{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-012810","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.716437+00:00","generated_at":"2026-06-12T13:49:57.470106+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Editas Q2 net loss $40.3M ($0.56/sh); cash $480M; EDIT-301 on track for 20 patients by year-end","bullets":["Net loss $40.3M ($0.56 per share) vs. $53.5M ($0.78) in Q2 2022.","Cash, cash equivalents and marketable securities $480.0M as of June 30, 2023.","EDIT-301 RUBY trial (SCD) on track to dose 20 total patients; clinical update by year-end.","EDIT-301 EDITHAL trial (TDT) commenced parallel dosing; update expected by year-end.","Erick Lucera appointed CFO and Linda C. Burkly, Ph.D. appointed CSO."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-012810","json":"https://secwatch.observer/filing/0001558370-23-012810.json","markdown":"https://secwatch.observer/filing/0001558370-23-012810.md","text":"https://secwatch.observer/filing/0001558370-23-012810.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000155837023012810/0001558370-23-012810-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000155837023012810/edit-20230802x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T13:49:57.470106+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a85433da0bc5a9a163e908c6e7ae579dfbff08ea","claim":"Editas Medicine, Inc. reported second quarter 2023 results: net income $40.3 million, EPS $0.56 per share.","evidence_excerpt":"For the three months ended June 30, 2023, net loss attributable to common stockholders was $40.3 million, or $0.56 per share, compared to net loss of $53.5 million, or $0.78 per share, for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650664/000155837023012810/0001558370-23-012810-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter 2023"},{"label":"Net income","value":"$40.3 million"},{"label":"EPS","value":"$0.56 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}